Absci Corporation is a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design. Absci Corporation is based in NEW YORK.
| Revenue (Most Recent Fiscal Year) | $2.80M |
| Net Income (Most Recent Fiscal Year) | $-115.18M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 167.23 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.43 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -4111.21% |
| Net Margin (Trailing 12 Months) | -4113.68% |
| Return on Equity (Trailing 12 Months) | -62.33% |
| Return on Assets (Trailing 12 Months) | -53.24% |
| Current Ratio (Most Recent Fiscal Quarter) | 6.57 |
| Quick Ratio (Most Recent Fiscal Quarter) | 6.57 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.26 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.23 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.88 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.85 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 153.02M |
| Free Float | 136.97M |
| Market Capitalization | $468.24M |
| Average Volume (Last 20 Days) | 4.52M |
| Beta (Past 60 Months) | 2.00 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 10.49% |
| Percentage Held By Institutions (Latest 13F Reports) | 52.05% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |